Abstract
between 0 and 48 hours after presentation (Figure 1d) . We took an open approach to analysis, without preconceived notions of expected dominance of certain molecular mechanisms, and initially included all possible variables from the data to avoid bias due to previous findings or hypotheses. The total starting data set consisted of the relative expression of a normalised set of 19766 genes from 75bp paired-end Illumina reads RNA-Seq data, integrated with 1383 protein abundances obtained using 10-plex Tandem Mass Tag (TMT), and abundances of 686 identified metabolites, curated according to containerized standards and are made openly available (link to 90 DataStore). After pre-processing, we created a combined data file consisting of 651 metabolites, 371 proteins and 19766 genes that was used as input.
To discover AP endotypes, we applied unsupervised clustering strategies to patient-topatient distance matrices, as in our previous work 13 . Specifically, we computed single time-point
Euclidean distances, area-under-the-curve (AUC) values within a principal component analysis (PCA) space, state-space trajectories in PCA space 14 and dynamic time warping (DTW) 15 distances. Once dissimilarity matrices were obtained, hierarchical clustering with the agglomerative Ward's method [16] [17] [18] was applied to create dendrograms and obtain clusters ( Figure   1e ). The stability of clusters was assessed by bootstrapping, using a 100 iterations with a random hold-out set and quantified using a Jaccard index (JI) of 0.5 as the dissolution point and a JI greater 100 than 0.75 to define stability 19 . These stability criteria were met by the AUC in PCA space method Table 2 and Supplementary Table   3 ).
Biological external validity was best for the AUC in PCA space clustering method over alternatives, based on pathway analysis using generalised linear model and the highly-annotated machine-readable KEGG pathway database as the biological gold standard 20 (extracted from both 110 5 R libraries GAGE 21 and MetaboAnalystR 22 ) and co-expression clusters derived from the FANTOM5 project 23, 24 as another biological input set. The number of FANTOM5, KEGG genes based and KEGG metabolites based hits for each clustering method is shown in Figure 1e . For the AUC+PCA method, the total percentage of variance explained by the first two components used was 51.5%, comprising 40.2% for PC1 and 11.3% for PC2. For this four-group solution, the silhouette score 25 based on the distance matrix was 0.39 (range 0.23 to 0.57) (Figure 1e ,
Supplementary Table 4).
If the maximum clinical utility is to be obtained from endotype assignation in AP, the endotype should be identifiable as close as possible to the time the affected individual seeks medical help. Using baseline data only, we computed variable importance in projection (VIP) 120 scores using a partial least square discriminant analysis algorithm (PLS-DA) applied to the Table 5 ). This was done rationally: each identified variable was cross-referenced with the following publicly available online resources 130
GeneCards (Weizmann Institute of Science), HUGO Gene Nomenclature Committee, NCBI EntrezGene, UniProtKB, Ensembl, NCBI PubChem, NCBI PubMed and Google Search, and semantic patterns were identified, discussed and agreed among the authors. Discernable features for the hypermetabolic endotype include GGT2 (g-glutamyl transferase 2) -glutathione homeostasis; GNAI1 (glucosamine 6-phosphate N-acetyltransferase); the caffeine metabolite products of arylamine N-acetyltransferase, 5-acetylamino-6-(+/-formyl)amino-3-methyluracil 26 ;
dopamine sulphate -a marker of increased gastrointestinal metabolism of endogenous dopamine 27 ;
citrulline -integral to the tricarboxylic acid cycle; and SPTSSB (serine palmitoyltransferase subunit B) -the rate-limiting enzyme for sphingolipid biosynthesis 28 . For the HPB endotype, the thematic features were CELA2A -pancreatic elastase 2; UDP-glucuronosyltransferase -which is 140 associated with Gilbert-type hyperbilirubinemia 29, 30 ; and SLCO1B7 -a liver-specific organic 6 anion transporter involved in bile secretion. All participants with AP-MODS clustered in the catabolic endotype, despite data on clinical outcome being initially withheld from the model (Figure 2b ). Although this finding was statistically significant (severe vs. non-severe, Fisher-Freeman Halton test, p=0.038), it is too early 160 to determine whether this would be replicated in a larger cohort. However, the etiology of AP was distributed evenly across endotypes (Fisher-Freeman Halton test, p=0.97) (Figure 2c) . Gender (Fisher-Freeman Halton test, p = 0.67) or time of onset of symptoms (ANOVA, p = 0.97) were not statistically significantly associated with endotype. Moreover, we generated a clustering for the AUC combined with PCA method using the residuals from a linear model which included gender, age and time of onset. The 4-cluster solution obtained using the corrected data was compared to the chosen partition and showed a high level of similarity (JI = 0.82 and distance matrices correlation, using a Mantel test, showed a correlation of 0.91 with an associated p-value of 0.01).
Independence between endotypes and systemic inflammatory response syndrome (SIRS) was tested for and was not rejected (SIRS vs no SIRS, Fisher-Freeman Halton test, p=0.097) 170
(Supplementary Figure 5) .
To externally validate the generalisability of our findings, we used our results in an independent dataset of AP patients, the KAPVAL cohort (Figure 3a) . KAPVAL (n = 312 patients, We computed Spearman's correlation (comparison of ranks, validated using t-distribution) for each pairwise comparison of groups from both cohorts, using metabolites that were not used to predict the group allocations (Figure 3e ). We obtained significant results when comparing 190 groups from IMOFAP cohort to their corresponding groups in KAPVAL cohort (correlation coefficients ranged from 0.29 to 0.61, corresponding p-values 2.20E-44, 2.37E-19, 1.28E-25 and 6.38E-10 for each endotype, respectively). This external validation demonstrated underlying biological similarity between corresponding endotypes and was unlikely to be observed by chance.
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Additionally, we noticed a similarity between our endotype analysis and a disease endotype reported in a related but distinct condition, acute respiratory distress syndrome (ARDS) 38 . Severe AP can cause ARDS, but there are multiple other causes of ARDS including sepsis, trauma, and major surgery 39 . We hypothesised that the hypermetabolic AP endotype reflects the same underlying disease process as the "Type 1" ARDS endotype reported by Calfee et al 35 . In order to test this hypothesis we matched measurements from our dataset with the measurements used to 200 define ARDS endotypes. We found 20 variables that matched the 31 variables in the ARDS study (6 physiological, 7 clinical biochemical, and 2 cytokine variables that were not used to produce 8 the clusterings, and 5 genes that were). There was a significant negative correlation (Spearman's) between the catabolic AP endotype with phenotype 1 in the two ARDS cohorts reported elsewhere (ALVEOLI p = 0.004; ARMA p < 0.001). Interestingly, the hypermetabolic AP endotype correlated positively with the ALVEOLI (p = 0.006) and ARMA cohorts (p < 0.001). (Figure 4a and Figure 4b ) using AVEOLI ordered variables. This provides compelling additional external validation for our observations and demonstrates that the endotypes or AP that we report here are generalisable to another type of critical illness.
Finally, we highlighted a significant overlap (Jaccard index 0.88) between our proposed 210 endotypes and groups highlighted using a multi-omics data integration framework, MOFA 40 , when using AUC values. We also noticed a great difference in structure between our endotypes and the ones highlighted using MOFA when applied to baseline KAPVAL data, confirming that, baseline data alone cannot be used directly to highlight the structure of AP endotypes and that previous knowledge of patient trajectories is required to generate the endotype models. Once established the models could be applied to presentation data.
In summary, our data confirm the existence of pathobiological mechanism-based endotypes in AP that could not otherwise be described using current clinical measures of severity or etiology. Using a novel serial evaluation approach, we identify four endotypes that passed stability and biological relevance validation, and that can be characterized by key pathways and 220 biomarker combination stereotypes into hypermetabolic, hepatopancreaticobiliary, catabolic and innate immune endotypes. These AP endotypes are statistically stable and externally validated.
Our findings represent a step-change advance in the understanding of acute pancreatitis and lay the foundation for prospective identification of individuals by endotype who may respond differentially to novel therapeutics as these emerge from the translational pipeline. 
Clinical sample and routine laboratory data acquisition
We used samples and clinical data from the IMOFAP cohort, which has been described in full previously 12 . In brief, consecutive emergency attendees to hospital with sudden onset abdominal pain with nausea and/or vomiting, and a serum amylase value greater than 100 iU/L were identified using an automated laboratory alert system with clinical verification, at all times of day or night for a period of three months. Confirmation of the diagnosis of AP according to the revised Atlanta 250 criteria 41 was made after recruitment in 57 of 79 recruited patients. For the integrated multiomic analysis presented here, we applied a further exclusion criterion to 3 patients who had a prolonged interval (greater than 200 hours) after symptom onset to first study sample, because we decided that those patients would have been likely to enter this study at a late point on their individual disease trajectory and thus introduce bias (Figure 1c) . The median time interval between symptom onset and recruitment in the 54 included patients was 21.3 hours (interquartile range 40.8 hours, Q1-Q3 13.5-54.4). Timed samples of peripheral venous blood were taken at recruitment and 3, 6, 12, 24, 48, 72 hours after that, and again at seven days. Samples were aliquoted into specific tubes containing appropriate preservation solution for subsequent DNA and RNA extraction, or serum and plasma extracts were prepared after centrifugation and snap frozen (Figure 1d ). Although 260 every effort was made to capture all time points, this was not always possible, and on occasion (for example, at the request of the patient to omit a short interval repeat venepuncture), time points were omitted. From this biobank, samples were selected for analysis based on the completeness of the multiomic set for a single individual. When analysing single time point data, and more precisely time point 0, we selected patients based on whether or not they had a complete multiomic set at time point 0, leaving 40 of the pre-selected 54 patients (consisting of 22 mild, 14 moderate and 4 severe AP cases). Differently, when comparing time-series we required at least two complete time points, selecting 34 patients (including 16 mild, 13 moderate and 5 severe AP cases).
We used samples and data from n = 312 patients from the KAPVAL cohort for validation.
The KAPVAL cohort is a fully-linked anonymised surplus biosample cohort which is made up of 270 samples and data from all patients presenting to the Royal Infirmary of Edinburgh with a serum amylase level > 300 iU/L (3-fold above the upper limit of the reference range for our laboratory).
An aliquot of gel-clot activator serum is retained and stored at -80 °C for all patient samples that have an elevated serum amylase. Using a linked anonymisation code, to which the investigators are blinded, the diagnosis of acute pancreatitis was confirmed by trained members of a specialist data collection team, using clinical and laboratory data obtained from the individuals electronic health record. The diagnosis of AP was made according to the revised Atlanta criteria 41 . Again, this data is not shared with the research team until it has been fully anonymised and all personal identifying information removed. A unique study identifier is used to subsequently link the serum sample with the clinical annotation prior to providing these to the investigator team. The variables 280 used in the analysis include age, gender, date and time of admission and discharge, first 3 diagnosis codes, standard clinical biochemistry and clinical haematology tests, level of critical care, duration of critical care and mortality. Serum samples were used as described.
Transcriptomic data acquisition and pre-processing 2.5 ml of peripheral venous blood was collected into the PAXgene Blood RNA Tube (BD Biosciences) following the manufacturer's instructions and stored at -80 °C until used. Total RNA was extracted and purified using the PAXgene Blood miRNA Kit (QIAGEN). The RNA integrity of total RNA samples was assessed using the Agilent 2100 Bioanalyzer. The mRNA in a total 11 RNA sample was converted into a library of template molecules of known strand origin using the 290 reagents provided in an Illumina® TruSeq® Stranded mRNA library prep workflow. The subsequent sequence data was obtained using Illumina HiSeq 4000 75PE system. RNA-Seq data consisted of 75bp paired-end Illumina reads stored as FASTQ files. One batch was carried out using polyA selection and the other using rRNA depletion. Samples were filtered based on QC results (FASTQC). Read alignment was performed against the genome assembly hg38 using STAR 42 . Counts were generated as a proxy for gene expression by assigning previously aligned reads to exons using the tool featureCounts 43 . hg38 genome was used as the reference genome.
The difference in RNA sequencing (library preparation) was accounted for using a protein-coding only filter, a batch removal algorithm (using the ARSyNseq function from NOISeq R library 44 ) and a normalisation step (FPKM). Finally, the normalised counts were transformed into Z-scores. 300
This allowed a comparison across samples. PCA plots of the counts before and after batch effect discarded. Scaling and linear imputation were applied using the minimum value for each compound, as any missing value would suggest a value below the detection limit. As samples from similar batches grouped together when performing the clustering step, we corrected for it using ComBat to remove the irrelevant variation between samples due to the different runs carried out.
Measurements were then transformed into Z-scores.
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Metabolomics data acquisition and pre-processing. Raw data were extracted, peak-identified and QC processed using Metabolon's hardware and software and compounds were identified by comparison to library entries of purified standards or recurrent unknown entities. Metabolite Quantification and Data Normalization: Peaks were quantified using area-under-the-curve. Where runs spanned multiple days, a data normalization step was performed to correct variation resulting from instrument inter-day tuning differences.
Metabolomics data consisted of an abundance list (raw ion counts). Data were pre-processed using a similar pipeline as the one used for the proteomics data but did not require a batch effect removal 360 step.
Data Analysis
Analyses were carried out using Python (version 3.5), R (version 3.3.2) and SPSS (IBM, v24).
Libraries used include dtwclust in R and numpy, pandas, rpy2, scipy, sklearn in Python. All methods used pre-processed Z-scores as initial input.
Single time point Euclidean distances
The first considered strategy consisted of computing Euclidean between all pairs of patients at selected time points, using pre-processed data. This was performed for time point 0, 24 and 48 370 hours individually and obtained measures were used as a way to quantify dissimilarity between individuals.
Area Under the Curve and PCA
For each variable and for all individuals we computed area under the curve (AUC) values for the corresponding time series using the trapezoidal rule and based on pre-processed values as described for each individual datatype. In doing so, each time series was summarised as a single value representing the cumulative magnitude of response over time. Consequently, values obtained for each variable could be treated as independent from others. We normalized the values based on the time difference between the first and last included time points. Using this newly created dataset 380 we projected the values on a principal component analysis plot where, selecting the first two components, we computed Euclidean distances between the different individuals. The Euclidean 14 distances were weighted according to the proportion of variance explained by each principal component so that the distance between two individuals on PC1 axis would weigh more in the final distance compared to the distance on PC2. PCA is a method of choice when encountering high dimensionality data, as much for data visualization as for data analysis, and is hypothesis free 45 . Indeed, PCA is only sensitive to the correlation structure in the data and does not make specific assumptions related to the stratification of the input data.
Trajectory through PCA space 390
As described in another study 14 , trajectories of patients through selected components can be helpful when clustering patients. Here we projected all time points of each individual onto a twodimensional PCA space and looked at their evolution through this newly defined space. To characterize the trajectory of an individual through this space we considered the direction taken between each pair of time points for these particular patients. We coded this direction with a value of 1, 2, 3 or 4 depending on the direction taken when dividing the space into four quadrants. This was repeated for all patients and eventually a vector of directions was obtained for each patient.
The Hamming distance was used to compare the vectors. When taking two vectors of the same length, the Hamming distance is computed by counting, in an element-wise fashion, the number of different elements. The values were then used as dissimilarity measures between patients. This 400 allowed to combine the advantages of PCA and trajectory analysis.
Dynamic Time Warping
Computation of distances between patients using dynamic time warping was carried out using the dtwclust package in R. The algorithm then considers each pair of samples. More specifically, for each variable, a matrix is generated and reports the difference in magnitude between all possible pairs of time points. One matrix of dimensions (time series 1 length*time series 2 length) is obtained for each variable. A summary matrix is generated for each patient by summing the individual matrices associated to each variable, element-by-element. The warping consists of finding a trajectory in that matrix that will minimize the distance between the two series. The 410 process will start from the matrix element corresponding to the first points of the two series being compared (in other terms the first element of the summary matrix) and will end when reaching the last series points (corresponding to the last element of the matrix). As this is performed on a summarized matrix, the selected warping represents a consensus alignment minimizing the summed differences in magnitude between the two multivariate time-series. From this warping a final distance is calculated and can be used as a dissimilarity value. We performed linear imputation on time series when time points were not equally spaced or missing. It was preferred as it allowed a fairer comparison when dealing with time series of different lengths/sampling pattern.
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Clustering strategy
Using the dissimilarity matrices previously obtained we clustered them using hierarchical clustering and Ward's method. Ward's method is an agglomerative method and works by minimizing distances within each group. Although it is usually used for Euclidean related distances (which is not the case for all the presented methods) it has been used successfully for other types of distance [16] [17] [18] and produced the best results here when compared with others (in terms of validation results).
The number of clusters was chosen according to the stability of each solution. For all number of clusters ranging from two to twenty we assessed this using bootstrapping combined with the Jaccard index. For a chosen number of clusters k we replaced individuals from the initial cohort to 430 create a new input dataset. It was then used to re-perform the clustering 100 times. Each one of the new results obtained was compared to the initial solution given k clusters. Each cluster from the k generated clusters was compared to the most similar cluster of the initial solution. The Jaccard index computed the overlap between the two and this was averaged for all matched groups that were part of a solution. After 100 repetitions we obtained a value for each k number of clusters by taking the average of the averaged Jaccard indexes and the solution with the highest value was chosen as the best one. Twenty was chosen as the maximum number as any greater value would have resulted in many clusters composed of one or very few individuals. This was not desirable as very little information could have been drawn from it. Additionally, we chose not to select for further analyses any solution with one group or more presenting less than three individuals. 440
Validation strategy
As bootstrapping with cluster comparisons produced a measure of stability, we used it to filter solutions based on a Jaccard index threshold of 0.75, meaning that when the initial dataset was 16 changed we would still get a sufficiently similar structure. Pathway analyses were carried out on pre-selected clusters and allowed to assess biological plausibility. To perform the analysis we filtered our pre-processed data to select only variable values reported at time point 0. Compound identifiers were converted when necessary using R package biomaRt. Data used consisted of KEGG pathways extracted from R package GAGE when analysing gene and protein data and from MetaboAnalystR when analysing metabolites. As four groups were identified, the aim was to 450 assess whether or not a subset of compounds (corresponding to a pathway) was associated with the group label. For each pathway this was tested using generalised linear models. A model was fitted to the data for each compound of a corresponding pathway with the group label being the This, this prevented overlapping pathways from biasing our results. R function anova with test="LRT" was used to do the tests. As the gene sets tested for enrichment were the same for each 460
one of the three methods tested to cluster individuals, p-values were used to quantify the biological relevance of a clustering. Each pathway with an associated value under the threshold of 0.05 was counted as differentially expressed and counts obtained for each method were compared to determine the most biologically relevant result. FANTOM5 data clusters were used to compare cell type gene signatures with our groups and thus allowing the discovery of closely involved cell types. The same strategy was applied to determine if a pathway was differentially expressed or not, using the same 5% cut-off.
Results were used as a way to quantify the biological pertinence, have an overall look at the results and select clustering solutions.
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Enrichment analysis
Partial Least Square Discriminant Analysis (PLS-DA), a classification algorithm, was used to highlight potential biomarkers and processes associated with single groups. The strategy was to create k models for k groups obtained, each model aiming at the classification of samples to the group of interest or others (regardless of which other group). Given group labels it will project the data onto a new space, given a number of components selected by the user, and then rotate the components to maximize the separation between samples of different groups. Finally, weights can be extracted and a correlation with each variable computed. This is called Variable Importance in Projection and the higher the value the more the variable will have contributed to the classifier model. We filtered variables deemed significant for the classification task using a VIP threshold 480 value of 1 for each one of the models obtaining respectively lists of size 10216, 6584, 9112 and 7037 for groups 1 to 4 (ref. 46 ). The lists were then used to perform pathway enrichment analysis.
To analyse the list produced for each group we first generated a Reactome database using files freely available from the Reactome website (https://reactome.org/download-data, lowest level pathway files). As our variables were of different type (transcriptomics, proteomics and metabolomics) we generated a merged pathway list using different Reactome files. Pathways were then selected for analysis if they had 10 or more compounds and no more than 500 as they were deemed neither robust nor informative. We then used Fisher's exact test to obtain a p-value per pathway based on the number of matches present in our list and the total number of compounds considered initially to be included in the list of interest. For each list p-values obtained from this 490 test were then corrected using an FDR based strategy and represented applying a threshold of 0.001 (Supplementary Figure 9) . Following the same strategy, time points 24 and 48 were also analysed and results added alongside the ones obtained for time point 0.
Data visualisation
An interactive webpage (available through URL) was created in order to visualise average AUC values and average z-score values over time for the identified endotypes. A subset of variables was selected using VIP scores from the PLS-DA models and a threshold of 2. In order to be able to visualise some of the clinical and cytokines measurements over time we filtered variables based on ANOVA results and a threshold of 0.05. 500
Validation in an independent dataset (KAPVAL)
To validate the groups previously highlighted we used a separate second cohort, the KAPVAL (Kynurenine pathway in AP, VALidation) cohort consisting of 312 individuals with confirmed AP as defined by the revised Atlanta criteria 41 . For these patients, clinical annotations as well as metabolomics data was available for a single time point corresponding to hospital admission. Prior
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to normalisation, only variables appearing in both datasets were kept. The data was then normalised in the same way as the IMOFAP metabolomics data, quantile normalisation was performed before transforming the values to Z-scores. To see if the same structure could be observed in both cohorts we classified KAPVAL samples using PLS-DA models (with 3 510 components) created for each one of the IMOFAP group but using solely metabolites that were available for the KAPVAL cohort as well. Admission IMOFAP data points were used as input to generate the models. VIP scores were computed and a threshold of 25 variables was set as a maximum of features to be included in each model. An optimal number of variables between 3 and 25 was selected based on R 2 values. To classify individuals from the KAPVAL cohort we applied each one of the models to our individual and allocated them to the group from which they were the closest to (Supplementary Figure 10) . To compare the biology between the groups of the two cohorts we computed average values per variable per group and compared them between the cohorts as inspired by Sweeney and al. 47 . We only compared metabolites that were not included in the PLS-DA models used to classify KAPVAL individuals (355 metabolites). To perform the 520 comparison between average values we computed Spearman's correlation (comparison of ranks, p-values computed using a t-distribution) for each pairwise comparison of groups from both cohorts (Figure 3e) . We obtained significant results when comparing groups from IMOFAP cohort to their corresponding groups in KAPVAL cohort (correlation coefficients ranged from 0.29 to 0.61, corresponding p-values 2.20E-44, 2.37E-19, 1.28E-25 and 6.38E-10 for each group label respectively). This allowed use to say that biology between corresponding groups was indeed similar and unlikely to be observed by chance.
Validation in an external dataset
To compare our endotypes to external data we used ARDS endotypes described in another study 35 . 530
From ARDS endotypes we extracted ranking of the variables used and compared it to rankings in each one of our endotypes. As not all ARDS reported variables were available in our dataset, we matched 20 variables that we used to extract and compare rankings. For each one of the two ARDS cohorts, we compared the lists of ranked variables to each one of our endotypes using Spearman's correlation coefficients. All coefficients were computed using Python scipy module. Significant results were obtained when comparing our catabolic AP endotype with phenotype 1 from both ALVEOLI and ARMA ARDS cohorts (p = 0.004 and p < 0.001). The correlation between our 19 hypermetabolic AP phenotype and ALVEOLI and ARMA cohorts was positive and significant as well (p = 0.006 and p < 0.001 respectively).
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Comparison with results from an independent tool (MOFAtools)
MOFA
40 allows to highlight, in a multi-omics dataset, variables explaining variation within a dataset, using factor analysis. Clustering analysis is available as part of the tools suite. We chose to run the analysis using AUC pre-computed values that were previously used to compute the distances within a PCA space and to highlight our endotype groups. Default parameters were used with the additional filter used to drop model factors explaining less than 1% of the variance in all omics. Once the model was built we chose to cluster the individuals using two latent factors and choosing a 4-cluster solution. When comparing our clusters to the ones obtained using MOFA we obtained an overlap of 0.88 as illustrated in Supplementary Figure 11 (computed using an averaged Jaccard index) and confirming the validity of our clusters. 550
Using our validation cohort (KAPVAL) and the available metabolomics data, pre-processed as described previously, we tested if the groups we obtained using PLS-DA models trained on IMOFAP data would highlight a similar structure in the dataset. As presented in Supplementary   Figure 12 , the overlap was quite low (Jaccard index value 0.37). We hypothesised that time-series data was required in order to structure the dataset and that some knowledge of the dynamics was required to classify patients using solely baseline data. 50  65  47  78  36  51  61  32  56  68  59  42  44  30  62  7  18  21  25  14  28  6  60  67  40  72  79  24  34  11  5  19   0   2   4   6   56  11  65  55  14  36  60  21  34  17  44  59  61  40  25  62  28  47  51  67  72  24  5  7  18  42  78  6  68  32  19  79  30  50   0e+00 2e+06 4e+06   55  17  32  56  47  65  36  61  78  28  42  59  50  44  68  14  6  72  40  67  5  11  7  51  18  79  19  24  34  60  30  62  21 
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